Hualan Biological Vaccine Inc. (SHE:301207)
China · Delayed Price · Currency is CNY 17.22
-0.48 (-2.71%)
Sep 11, 2026, 3:04 PM CST
Hualan Biological Vaccine Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,186 | 1,201 | 1,126 | 2,409 | 1,824 | 1,830 |
Other Revenue | 1.3 | 1.3 | 1.83 | 1.2 | 1.57 | - |
| 1,187 | 1,203 | 1,128 | 2,410 | 1,826 | 1,830 | |
Revenue Growth | 3.01% | 6.62% | -53.21% | 32.03% | -0.23% | -24.59% |
Cost of Revenue | 333.47 | 325.15 | 286.78 | 382.02 | 369.19 | 354.01 |
Gross Profit | 853.46 | 877.36 | 841.03 | 2,028 | 1,456 | 1,476 |
Selling, General & Admin | 575.91 | 594.8 | 582.54 | 1,019 | 776.35 | 647.5 |
Research & Development | 112.76 | 151.3 | 162.64 | 91.11 | 134.64 | 144.13 |
Other Operating Expenses | 12.35 | 10.24 | 10.61 | 15.18 | 12.59 | 10.84 |
Operating Expenses | 729.49 | 787.09 | 746.39 | 1,146 | 952.36 | 803.51 |
Operating Income | 123.98 | 90.27 | 94.64 | 881.98 | 504.09 | 672.29 |
Interest Expense | - | -2.55 | -6.1 | -6.08 | -10.69 | -13.32 |
Interest & Investment Income | 70.57 | 81.25 | 89.29 | 81.93 | 72.01 | 28.82 |
Currency Exchange Gain (Loss) | -0.05 | -0.05 | 0.06 | -0.23 | -0.11 | 0.25 |
Other Non Operating Income (Expenses) | 0.96 | -0.04 | -0.08 | -0.15 | 0.08 | -0.19 |
EBT Excluding Unusual Items | 195.46 | 168.88 | 177.81 | 957.44 | 565.37 | 687.85 |
Gain (Loss) on Sale of Investments | 9.93 | 12.73 | 24.3 | 39.68 | 16.85 | 14.25 |
Gain (Loss) on Sale of Assets | -0.2 | -0.2 | -0.14 | -0.2 | 0.63 | - |
Asset Writedown | 0.36 | -0.1 | -0.24 | -0.25 | -0.05 | -1 |
Other Unusual Items | 6.48 | 6.48 | 12.82 | 10.21 | 6.68 | 4.65 |
Pretax Income | 212.04 | 187.79 | 214.55 | 1,007 | 589.48 | 705.75 |
Income Tax Expense | 13.47 | 4.87 | 9.03 | 146.91 | 69.84 | 84.78 |
Net Income | 198.57 | 182.92 | 205.52 | 859.97 | 519.63 | 620.97 |
Net Income to Common | 198.57 | 182.92 | 205.52 | 859.97 | 519.63 | 620.97 |
Net Income Growth | -1.23% | -11.00% | -76.10% | 65.50% | -16.32% | -32.86% |
Shares Outstanding (Basic) | 596 | 595 | 598 | 601 | 590 | 540 |
Shares Outstanding (Diluted) | 596 | 595 | 598 | 602 | 590 | 540 |
Shares Change | 0.11% | -0.51% | -0.71% | 2.03% | 9.33% | 0.01% |
EPS (Basic) | 0.33 | 0.31 | 0.34 | 1.43 | 0.88 | 1.15 |
EPS (Diluted) | 0.33 | 0.31 | 0.34 | 1.43 | 0.88 | 1.15 |
EPS Growth | -1.33% | -10.54% | -75.93% | 62.20% | -23.46% | -32.86% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 405.28 | 347.43 | 416.45 | 825.42 | 196.01 | -66.73 |
Free Cash Flow Per Share | 0.68 | 0.58 | 0.70 | 1.37 | 0.33 | -0.12 |
Dividend Per Share | 1.400 | 1.400 | 0.200 | 0.600 | 0.200 | 0.133 |
Dividend Growth | 600.00% | 600.00% | -66.67% | 200.00% | 50.04% | - |
Gross Margin | 71.91% | 72.96% | 74.57% | 84.15% | 79.78% | 80.65% |
Operating Margin | 10.45% | 7.51% | 8.39% | 36.59% | 27.61% | 36.74% |
Profit Margin | 16.73% | 15.21% | 18.22% | 35.68% | 28.46% | 33.94% |
Free Cash Flow Margin | 34.14% | 28.89% | 36.93% | 34.24% | 10.74% | -3.65% |
EBITDA | 265.44 | 231.35 | 235.02 | 1,022 | 638.51 | 740.2 |
EBITDA Margin | 22.36% | 19.24% | 20.84% | 42.41% | 34.98% | 40.45% |
D&A For EBITDA | 141.46 | 141.08 | 140.38 | 140.33 | 134.42 | 67.91 |
EBIT | 123.98 | 90.27 | 94.64 | 881.98 | 504.09 | 672.29 |
EBIT Margin | 10.45% | 7.51% | 8.39% | 36.59% | 27.61% | 36.74% |
Effective Tax Rate | 6.35% | 2.59% | 4.21% | 14.59% | 11.85% | 12.01% |
Revenue as Reported | 1,187 | 1,203 | 1,128 | 2,410 | 1,826 | 1,830 |